Metformin Accord (Metformin Hydrochloride)

Metformin acts primarily by inhibiting hepatic glucose production and enhancing peripheral insulin sensitivity. It activates the enzyme AMP‑activated protein kinase (AMPK), which regulates metabolic pathways, leading to reduced gluconeogenesis, decreased intestinal glucose absorption, and improved uptake of glucose by muscle cells.

The specific dose of Metformin Accord is determined by the prescribing clinician based on the individual’s renal function, glycaemic targets, and tolerability. Dosage adjustments are made during treatment to achieve optimal blood‑sugar control while minimizing side effects.

Metformin may be used during pregnancy when the benefits outweigh potential risks, particularly in women with gestational diabetes or pre‑existing type 2 diabetes. However, safety data are limited, and the decision should be made by a healthcare professional. Metformin is excreted in breast milk; breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metformin is a first‑line oral agent distinguished by its ability to lower glucose without causing hypoglycaemia when used alone. Compared with sulfonylureas, it does not stimulate insulin release, reducing the risk of low blood sugar. Unlike newer agents such as SGLT2 inhibitors, metformin is less expensive and has a long safety record, though it requires renal monitoring.

Metformin Accord should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metformin Accord is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. The prescribing clinician will advise the appropriate dosing schedule, which may involve once‑daily or divided doses.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or after exposure to iodinated contrast media. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant hepatic dysfunction.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those who have experienced lactic acidosis while on the drug. It should also be avoided in patients undergoing radiographic studies with iodinated contrast unless renal function is closely monitored.